|Dr. Thomas J. Schall Ph.D.||Founder, Pres, CEO & Chairman||1.13M||23.5M||1959|
|Ms. Susan M. Kanaya||Exec. VP, Chief Financial & Admin. Officer, Sec. and Director||757.77k||14.74M||1963|
|Dr. Rita I. Jain M.D.||Exec. VP, Chief Medical Officer & Exec. Employee Director||76k||N/A||1963|
|Dr. Markus J. Cappel Ph.D.||Sr. VP, Chief Bus. Officer & Treasurer||607.52k||18.44M||1961|
|Mr. Tausif Butt||Exec. VP & COO||N/A||N/A||1966|
|Ms. Kari E. Leetch||Sr. VP of HR||N/A||N/A||N/A|
|Ms. Dalia R. Rayes||Sr. VP & Head of Commercial||N/A||N/A||N/A|
|Dr. Sangita Ghosh Ph.D.||Sr. VP of Technical Operations||N/A||N/A||N/A|
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The company is also developing CCX559, an orally-administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally-administered inhibitor of the chemokine receptor CC9, which has completed Phase I clinical trial or the treatment of inflammatory bowel disease. In addition, it develops CCX587 for the treatment of TH17 driven diseases. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.
ChemoCentryx, Inc.’s ISS governance QualityScore as of 26 September 2021 is 4. The pillar scores are Audit: 7; Board: 4; Shareholder rights: 5; Compensation: 5.